[1] Ripoll C, Groszmann R, Garcia-Tsao G, et al. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis[J]. Gastroenterology, 2007,133(2):481-488.
[2] Villanueva C, Albillos A, Genesca J, et al. Development of hyperdynamic circulation and response to beta-blockers in compensated cirrhosis with portal hypertension[J]. Hepatology, 2016,63(1):197-206.
[3] Villanueva C, Albillos A, Genescà J, et al. β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial[J].Lancet, 2019,393(10181):1597-1608.
[4] de Franchis R, Bosch J, Garcia-Tsao G, et al. Baveno Vll-Renewing consensus in portal hypertension[J]. J Hepatol, 2022,76(4):959-974.
[5] Reiberger T, Ulbrich G, Ferlitsch A, et al. Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol[J]. Gut, 2013,62(11):1634-1641.
[6] Dulin B, Abraham W T. Pharmacology of carvedilol[J]. Am J Cardiol, 2004,93(9A):3B-6B.
[7] Albillos A, Lledo J L, Banares R, et al. Hemodynamic effects of alpha-adrenergic blockade with prazosin in cirrhotic patients with portal hypertension[J]. Hepatology, 1994,20(3):611-617.
[8] Garcia-Pagan J C, Morillas R, Banares R, et al. Propranolol plus placebo versus propranolol plus isosorbide-5-mononitrate in the prevention of a first variceal bleed: a double-blind RCT[J]. Hepatology, 2003,37(6):1260-1266.
[9] Bañares R, Moitinho E, Piqueras B, et al. Carvedilol, a new nonselective beta-blocker with intrinsic anti-alpha1-adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis[J]. Hepatology, 1999,30(1):79-83.
[10] Banares R, Moitinho E, Matilla A, et al. Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis[J]. Hepatology, 2002,36(6):1367-1373.
[11] Sinagra E, Perricone G, D'Amico M, et al. Systematic review with meta-analysis: the haemodynamic effects of carvedilol compared with propranolol for portal hypertension in cirrhosis[J]. Aliment Pharmacol Ther,2014,39(6):557-568.
[12] Tripathi D, Therapondos G, Lui H F, et al. Haemodynamic effects of acute and chronic administration of low-dose carvedilol, a vasodilating beta-blocker, in patients with cirrhosis and portal hypertension[J].Aliment Pharmacol Ther,2002,16(3):373-380.
[13] Schwarzer R, Kivaranovic D, Paternostro R, et al. Carvedilol for reducing portal pressure in primary prophylaxis of variceal bleeding: a dose-response study[J]. Aliment Pharmacol Ther, 2018,47(8):1162-1169.
[14] Groszmann R J, Garcia-Tsao G, Bosch J, et al. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis[J]. N Engl J Med, 2005,353(21):2254-2261.
[15] Bhardwaj A, Kedarisetty C K, Vashishtha C, et al. Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial[J]. Gut, 2017,66(10):1838-1843.
[16] Mandorfer M, Peck-Radosavljevic M, Reiberger T. Prevention of progression from small to large varices: are we there yet? An updated meta-analysis[J]. Gut, 2017,66(7):1347-1349.
[17] Villanueva C, Torres F, Sarin S K, et al. Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a competing-risk meta-analysis[J]. J Hepatol, 2022,77(4):1014-1025.
[18] Sharma M, Singh S, Desai V, et al. Comparison of therapies for primary prevention of esophageal variceal bleeding: a systematic review and network meta-analysis[J]. Hepatology, 2019,69(4):1657-1675.
[19] Tripathi D, Ferguson J W, Kochar N, et al. Randomized controlled trial of carvedilol versus variceal band ligation for the prevention of the first variceal bleed[J]. Hepatology, 2009,50(3):825-833.
[20] McDowell H R, Chuah C S, Tripathi D, et al. Carvedilol is associated with improved survival in patients with cirrhosis: a long-term follow-up study[J]. Aliment Pharmacol Ther, 2021,53(4):531-539.
[21] Malandris K, Paschos P, Katsoula A, et al. Carvedilol for prevention of variceal bleeding: a systematic review and meta-analysis[J]. Ann Gastroenterol, 2019,32(3):287-297.
[22] Sinha R, Lockman K A, Mallawaarachchi N, et al. Carvedilol use is associated with improved survival in patients with liver cirrhosis and ascites[J]. J Hepatol, 2017,67(1):40-46.
[23] Jachs M, Hartl L, Simbrunner B, et al. Carvedilol achieves higher hemodynamic response and lower rebleeding rates than propranolol in secondary prophylaxis[J]. Clin Gastroenterol Hepatol, 2023,21(9):2318-2326.
[24] Bakris GL, Fonseca V, Katholi RE, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial[J]. JAMA, 2004,292(18):2227-2236. |
